PRESENT
The current study identified ARL4C as a PD-associated gene by an in silico analysis using three GC data sets. 6 High mRNA expression of ARL4C was significantly associated with depth of invasion and PD in another data set for confirmation. Moreover, high expression of ARL4C was a poor prognostic factor in three independent GC data sets. In GC cells, ARL4C knockdown reduced invasion/migration capacity, SLUG expression, and formation of lamellipodia. The expression of ARL4C was induced by epidermal growth factor (EGF) treatment in GC cells. This study also showed that high expression of ARL4C positively correlated with epithelial-mesenchymal transition (EMT) gene set in gene set-enrichment analysis (GSEA).
FUTURE
The current study suggested that ARL4C was a PD-associated gene, possibly through promoting invasive capacity by activation of both EMT and motility in GC. However, further in vitro studies and in vivo evaluations are required in the future. Furthermore, the mechanism of ARL4C-induced EMT should be clarified in detail. It may be that ARL4C is an attractive therapeutic target for PD in GC. Therefore, the inhibitors of ARL4C should be identified in the future. DISCLOSURE There are no conflicts of interest.
